Back to Search Start Over

The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma

Authors :
Mackay, T.M.
Smits, F.J.
Roos, D.
Bonsing, B.A.
Bosscha, K.
Busch, O.R.
Creemers, G.J.
Dam, R.M. van
Eijck, C.H.J. van
Gerhards, M.F.
Groot, J.W.B. de
Koerkamp, B.G.
Mohammad, N.H.
Harst, E. van der
Hingh, I.H.J.T. de
Homs, M.Y.V.
Kazemier, G.
Liem, M.S.L.
Meijer, V.E. de
Molenaar, I.Q.
Nieuwenhuijs, V.B.
Santvoort, H.C. van
Schelling, G.P. van der
Stommel, M.W.J.
Tije, A.J. ten
Vos-Geelen, J. de
Wit, F.
Wilmink, J.W.
Laarhoven, H.W.M. van
Besselink, M.G.
Dutch Pancreatic Canc Grp
Graduate School
AGEM - Digestive immunity
AGEM - Endocrinology, metabolism and nutrition
AGEM - Re-generation and cancer of the digestive system
CCA - Cancer Treatment and Quality of Life
Surgery
Oncology
CCA - Cancer Treatment and quality of life
Medical Oncology
Groningen Institute for Organ Transplantation (GIOT)
Center for Liver, Digestive and Metabolic Diseases (CLDM)
RS: NUTRIM - R2 - Liver and digestive health
MUMC+: MA Heelkunde (9)
Interne Geneeskunde
MUMC+: MA Medische Oncologie (9)
RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Source :
HPB: The official journal of the International Hepato Pancreato Biliary Association, 22(2), 233-240. John Wiley and Sons Inc., Hpb, 22, 2, pp. 233-240, International Hepato-Pancreato Biliary Association., 22(2), 233. John Wiley and Sons Inc., HPB, 22(2), 233-240. ELSEVIER SCI LTD, HPB, 22(2), 233-240. John Wiley and Sons Inc., HPB, 22(2), 233-240. John Wiley & Sons Inc., Hpb, 22(2), 233-240. ELSEVIER SCI LTD, Mackay, T M, Smits, F J, Roos, D, Bonsing, B A, Bosscha, K, Busch, O R, Creemers, G-J, van Dam, R M, van Eijck, C H J, Gerhards, M F, de Groot, J W B, Groot Koerkamp, B, Haj Mohammad, N, van der Harst, E, de Hingh, I H J T, Homs, M Y V, Kazemier, G, Liem, M S L, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, van Santvoort, H C, van der Schelling, G P, Stommel, M W J, ten Tije, A J, de Vos-Geelen, J, Wit, F, Wilmink, J W, van Laarhoven, H W M, Besselink, M G & Dutch Pancreatic Cancer Group 2020, ' The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis ', HPB, vol. 22, no. 2, pp. 233-240 . https://doi.org/10.1016/j.hpb.2019.06.019, Hpb, 22, 233-240
Publication Year :
2020
Publisher :
ELSEVIER SCI LTD, 2020.

Abstract

Contains fulltext : 226028.pdf (Publisher’s version ) (Closed access) BACKGROUND: The relation between type of postoperative complication and not receiving chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The aim was to investigate which patient factors and postoperative complications were associated with not receiving adjuvant chemotherapy. METHODS: Patients who underwent resection (2014-2017) for PDAC were identified from the nationwide mandatory Dutch Pancreatic Cancer Audit. The association between patient-, tumor-, center-, treatment characteristics, and the risk of not receiving adjuvant chemotherapy was analyzed with multivariable logistic regression. RESULTS: Overall, of 1306 patients, 24% (n = 312) developed postoperative Clavien Dindo ≥3 complications. In-hospital mortality was 3.5% (n = 46). Some 433 patients (33%) did not receive adjuvant chemotherapy. Independent predictors (all p

Details

Language :
English
ISSN :
1365182X
Volume :
22
Issue :
2
Database :
OpenAIRE
Journal :
Hpb
Accession number :
edsair.doi.dedup.....bab622c8bf9a5f70c9a901ded91a0d35
Full Text :
https://doi.org/10.1016/j.hpb.2019.06.019